NCT01525082 2024-02-06Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsStanford UniversityPhase 2 Completed20 enrolled 15 charts
NCT00869050 2016-07-25Capecitabine and Temozolomide for Neuroendocrine CancersColumbia UniversityPhase 2 Completed41 enrolled 9 charts
NCT00602082 2013-08-07Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine TumorsNational Cancer Institute (NCI)Phase 2 Completed84 enrolled